NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (CVLB) (“Conversion Labs” or “Company”), an e-commerce and telemedicine company focused on creating and scaling proprietary health and wellness brands, today announced its official launch of Rex MD, a male-oriented telemedicine brand.

Customers can now visit where they can be diagnosed and prescribed prescription medications that are discretely delivered to their home.  Rex MD is initially focused on the treatment of erectile dysfunction and will offer additional prescription medications for men in the coming months.

Due to trends such as rising internet proficiency, rising healthcare costs, and customer demand for convenience, the global telemedicine market is expected to reach $130 billion by 2025 according to Global Market Insights. Expected to grow at a compounded annual growth rate of over 19%, telemedicine is currently one of the fastest growing segments in healthcare.

“We have been preparing to enter the rapidly growing telemedicine space since the beginning of the year,” stated Justin Schreiber, Chairman and CEO of Conversion Labs, Inc. “Our launch of Rex MD represents the culmination of our efforts in creating a robust telemedicine technology infrastructure in addition to receiving the stringent certifications required to operate in this emerging space. Given our company’s core competency in acquiring customers scalably and profitably, we expect great things from our telemedicine launch as Rex MD grows in both market share and presence.”

About Conversion Labs

Conversion Labs, Inc is a health and wellness focused e-commerce company with a portfolio of online direct-to-consumer brands. The company’s portfolio of brands includes proprietary over-the-counter products and prescription medications. The company also provides online, virtual physician consultations to consumers in 48 states. In addition to its healthcare platform, Conversion Labs is the majority shareholder of PDF Simpli, a direct to consumer SaaS business for editing, signing, and sharing PDF documents. To learn more about our corporate strategy, brands, or for investor relations please visit or email us at

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other thing, statements regarding the offering, the expected gross proceeds, the expected use of proceeds and the expected closing of the offering. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.